dexamethasone injection / Generic mfg. - LARVOL DELTA

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "The significantly improved overall survival and patient-reported measures in CARTITUDE-4 reinforce the use of cilta-cel in treating relapsed or refractory multiple myeloma as early as after first relapse."

Journal • P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology

Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

New trial • Anesthesia

Intraperitoneal Dexamethasone Spraying on Vagal Nerve-Rich Areas for Prevention of Hoarseness After Upper Abdominal Surgery (clinicaltrials.gov) - P=N/A | N=584 | Recruiting | Sponsor: Fujian Medical University Union Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Otorhinolaryngology

Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study. (PubMed, Int J Clin Oncol) - "An institutional dexamethasone-premedication strategy was associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab. Exploratory analyses found no significant differences in response or PFS; adequately powered studies with longer follow-up should determine whether dexamethasone premedication affects antitumor efficacy."

Journal • Oncology • Solid Tumor • Urothelial Cancer

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study. (PubMed, Lancet Haematol) - P3 | "Final overall survival analysis in the BELLINI study showed overall survival favouring placebo over venetoclax and progression-free survival favouring venetoclax over placebo, indicating venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population."

Journal • P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study (ASH 2024) - P3 | "Pts received Isa (10 mg/kg IV) in the Isa-VRd arm and bortezomib (1.3 mg/m2 SC), lenalidomide (25 mg PO), and dexamethasone (20 mg IV/PO) in both arms. More pts had positive-to-negative conversions with Isa-VRd vs VRd, with conversion events increasing over the maintenance period. These data support the benefit of Isa in addition to VRd as initiation therapy, as well as the addition of Isa to Rd during maintenance in transplant-ineligible pts with NDMM."

Clinical • Minimal residual disease • P3 data • Residual disease • Hematological Malignancies • Multiple Myeloma • Oncology

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial. (PubMed, Lancet Oncol) - P2 | "OPTIMUM shows sustained progression-free survival and overall survival improvement with risk-stratified extended therapy, supporting implementation of molecular diagnostics and tailored treatment in patients with newly diagnosed high-risk multiple myeloma."

Journal • P2 data • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Transplantation

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. (PubMed, Lancet Haematol) - P3 | "HRQOL was generally maintained or improved over time with belantamab mafodotin, bortezomib, and dexamethasone treatment. Our findings, in conjunction with previously reported clinical benefits, support the use of belantamab mafodotin as a potential new standard of care in relapsed or refractory multiple myeloma."

Journal • P3 data • Hematological Malignancies • Multiple Myeloma • Oncology

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. (PubMed, Lancet) - P3 | "Adding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT. Adding ibrutinib during induction and as maintenance should be part of first-line treatment of younger mantle cell lymphoma patients. Whether ASCT adds to an ibrutinib-containing regimen is not yet determined."

Head-to-Head • Journal • P3 data • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Oncology • Transplantation

A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). (PubMed, Ann Oncol) - "Olanzapine 5mg for 6 days with 5-HT3RA and dexamethasone appears effective for T-DXd-treated patients to prevent delayed and persistent nausea and vomiting."

Clinical • Journal • P2 data • Anorexia • Breast Cancer • Diabetes • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. (PubMed, Lancet) - P3 | "The addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population."

Clinical • Journal • P3 data • Hematological Malignancies • Multiple Myeloma • Oncology

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. (PubMed, Lancet) - P3 | "Mezigdomide-carfilzomib-dexamethasone provided a significant PFS benefit compared with carfilzomib-dexamethasone alone, with higher rates of grade 3 or 4 adverse events, including infections, which were mostly manageable with standard clinical practice and supportive care. These findings support mezigdomide-carfilzomib-dexamethasone as a clinically meaningful treatment option as early as first relapse in predominantly triple-class-exposed, anti-CD38 antibody-refractory and lenalidomide-refractory patients, a growing population with substantial unmet need."

Journal • P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Targeted Protein Degradation • CRBN • IKZF1

CarMob: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Hackensack Meridian Health | Trial completion date: Sep 2026 ➔ Aug 2027 | Trial primary completion date: Sep 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial. (PubMed, Lancet Haematol) - P3 | "At the time of the current analysis, a difference in overall survival could not be detected between the treatment groups, and no new safety signals were observed. Collectively, the evidence suggests that isatuximab plus carfilzomib-dexamethasone is a key treatment for patients with relapsed or refractory multiple myeloma."

Journal • P3 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Respiratory Diseases

Neonatal Aicardi-Goutières syndrome presenting with macrophage activation syndrome-like hyperinflammation and severe congenital glaucoma: a case report. (PubMed, Pediatr Rheumatol Online J) - "This case illustrates the clinical overlap between neonatal AGS and MAS-like hyperinflammation, underscores the potential role of early mechanism-based therapy in selected critically ill neonates with suspected interferonopathy, and emphasizes the importance of comprehensive genomic evaluation when severe ocular disease accompanies AGS. The identified CYP1B1 variant provides a strong molecular explanation for the patient's congenital glaucoma."

Journal • Aicardi Goutieres Syndrome • Genetic Disorders • Glaucoma • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Interferonopathies • Ophthalmology • Rare Diseases • CYP1B1 • JAK1 • RNASEH2B

Life-threatening anaphylactic shock induced by cadonilimab (AK104), a PD-1/CTLA-4 bispecific antibody: a case report. (PubMed, Front Pharmacol) - "Emergency treatment included subcutaneous epinephrine 0.5 mg, intramuscular diphenhydramine 20 mg, intravenous dexamethasone 10 mg, aggressive fluid resuscitation, and supplemental oxygen...The patient had a documented prior hypersensitivity to paclitaxel but no prior exposure to immune checkpoint inhibitors...Cadonilimab may rarely cause rapid-onset, life-threatening anaphylactic shock during the first infusion. Careful monitoring, immediate access to emergency management-including vasopressor support-and heightened awareness of bispecific antibody-associated hypersensitivity are essential."

Journal • Allergy • Cardiovascular • Cervical Cancer • Cervical Squamous Cell Carcinoma • Dermatology • Hypotension • Immunology • Infectious Disease • Oncology • Pruritus • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • CTLA4 • PD-1

Optimal Head Position for Intratympanic Dexamethasone Injection Relative to the Round Window. (PubMed, Otol Neurotol) - "Ideal intratympanic dexamethasone delivery requires adjustment of roll and pitch in addition to yaw. Implementing a 3-axis ideal head position is a simple, cost-effective strategy to improve intratympanic steroid absorption and therapeutic efficacy."

Journal • Anesthesia • Brain Cancer • Oncology • Otorhinolaryngology • Solid Tumor

The Impact of Regional Motor-sparing Blocks on Early Rehabilitation Following Primary Hip or Knee Arthroplasty (clinicaltrials.gov) - P=N/A | N=220 | Not yet recruiting | Sponsor: Poznan University of Physical Education

New trial • Orthopedics

PDT-rGBM: Microsurgical Resection Combined With Photodynamic Therapy for Recurrent Glioblastoma (clinicaltrials.gov) - P=N/A | N=10 | Active, not recruiting | Sponsor: Yonggao Mou

New trial • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

The Effect of Dexamethasone on Short Term Patient Response: IV vs Oral Administration (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: The University of Texas Health Science Center at San Antonio

New P1/2 trial • Dental Disorders • Pain • Periodontitis

Optimizing perioperative intravenous corticosteroid dosing for postoperative outcomes in total joint arthroplasty: a network meta-analysis. (PubMed, Knee) - "Low-dose dexamethasone generally provides adequate benefits, while higher doses may provide additional analgesia in TKA or patients at risk of severe postoperative pain."

Journal • Retrospective data • Orthopedics • Pain

DEXA-REFINE: Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions (clinicaltrials.gov) - P4 | N=980 | Completed | Sponsor: Hospital Universitario de Gran Canaria Doctor Negrín | Recruiting ➔ Completed

Trial completion • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Hearing Outcomes After Intratympanic Dexamethasone for Sudden Sensorineural Hearing Loss (AAO-HNSF 2026) - "Introduction: Intratympanic dexamethasone injections are commonly used to treat sudden sensorineural hearing loss (SSNHL), yet optimal dosing remains unclear... In this retrospective cohort, higher dexamethasone concentration and greater injection frequency were not associated with improved audiologic outcomes, suggesting escalation within commonly used dosing ranges may not confer additional benefit."

Otorhinolaryngology

Idiopathic Sudden Sensorineural Hearing Loss : Role of Different Treatment Modalities --prospective Interventional Cohort Study (AAO-HNSF 2026) - "Group A: ITS +AV (antiviral)+BH (Betahistine as vasodilator).Group B: CS (Oral Corticosteroid)- Prednisolone 1mg/kg body weight with tapering dose for 3 weeks. Group C: ITS (Intratympanic steroid) 0.3 ml Injection Dexamethasone by intratympanic route with 26 gauze spinal needle with bi-weekly doses of 6 injections... The ITS group showed the most significant improvement in hearing loss with complete recovery in 60% patients. The ITS+AV+BH group showed considerable improvement, oral corticosteroid group showed least improvement"

Clinical • Otorhinolaryngology